Key result
A personalized approach to antithrombotic therapy in patients with unstable angina undergoing CABG reduced repeated cardiovascular events over 2 years compared to standard treatment (5% vs 22.6%).
Why the study?
The study was conducted to evaluate clinical outcomes and platelet-plasma and vascular hemostasis in patients with unstable angina undergoing on-pump or off-pump CABG to guide antithrombotic therapy and reduce postoperative cardiovascular events.
Does a personalized approach to antithrombotic therapy reduce repeated cardiovascular events in patients with unstable angina undergoing CABG?
Cohort (n=146)
Does a personalized approach to antithrombotic therapy reduce repeated cardiovascular events in patients with unstable angina undergoing CABG?
A personalized approach to antithrombotic therapy based on hemostasis monitoring may significantly reduce long-term cardiovascular events in patients with unstable angina undergoing CABG.
The aim. To evaluate the clinical outcomes and features of the state of the platelet-plasma and vascular hemostasis in patients (pts) with unstable angina and coronary artery bypass grafting (CABG) on-pump and off-pump for the correction of antithrombotic therapy and reduce the number of postoperative cardiovascular events. Material and methods. The study included 146 pts with unstable angina (UA) with a surgical treatment strategy. CG amounted to 106 pts with CABG and a standard approach to drug maintenance. MG comprised 40 pts with CABG and a personalized approach to antithrombotic therapy. Results. In CABG off-pump in pts with UA, an increased in platelet aggregation and activation of platelet hemostasis occurs on the 2nd day of the postoperative period, in CABG on-pump on the 5-7th day. Activation of plasma hemostasis had laboratory manifestations on the 5-7th day of the postoperative period, and is most pronounced in CABG on-pump, compared with CABG off-pump. After 1 month of control, 38,7% pts with UA and CABG were characterized by the presence of high residual platelet reactivity against the background of standard antiplatelet treatment, of which 23,6% retained activation of plasma hemostasis, which is manifested in excess of the normal level of D-dimers, as well as an increased in peak thrombin concentration and endogenous thrombin potential. Patients with UA and CABG who underwent correction of antithrombotic therapy differed from patients with a standard approach to treatment with a significantly lower number of repeated cardiovascular events over 2 years of follow-up (5% versus 22.6%).
No takes yet. Share an insight, caveat, or question.
Medvedeva et al. (2021) conducted a cohort in Unstable angina and coronary artery bypass grafting (n=146). Personalized approach to antithrombotic therapy vs. Standard approach to drug maintenance was evaluated on Repeated cardiovascular events. A personalized approach to antithrombotic therapy in patients with unstable angina undergoing CABG reduced repeated cardiovascular events over 2 years compared to standard treatment (5% vs 22.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: